Precision medicine for KRAS wild-type pancreatic adenocarcinomas
- 15 December 2023
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 197, 113497
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real‐world studyCancer Medicine, 2018
- A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinomaJournal of Gastrointestinal Oncology, 2018
- Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical PhenotypeClinical Cancer Research, 2017
- Genomic analyses identify molecular subtypes of pancreatic cancerNature, 2016
- Molecular Pathogenesis of Pancreatic Cancer2016
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS MutationsMolecular Cancer Research, 2015
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targetsNature Communications, 2015
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011